Here are the 10-K annual reports from Maze Therapeutics, Inc. (MAZE) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow MAZE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MAZE filings page.
Maze Therapeutics files its annual report outlining rapid progress in kidney and metabolic disease programs built on its human genetics–driven Compass platform. The company is a clinical-stage biopharma with no product revenue, focused on small‑molecule precision medicines.
Lead candidate MZE829, an APOL1 inhibitor for APOL1‑mediated kidney disease, showed positive Phase 2 proof‑of‑concept data, with a 35.6% mean reduction in urinary albumin‑to‑creatinine ratio at week 12 in evaluable patients and larger reductions in key subgroups. Maze plans to continue Phase 2 enrollment and move into pivotal development.
MZE782, targeting SLC6A19, completed a Phase 1 trial in healthy volunteers, was well tolerated, and produced large, dose‑dependent increases in urinary phenylalanine excretion, supporting Phase 2 trials in phenylketonuria and chronic kidney disease planned for 2026. The report also highlights partnered programs, including MZE001 for Pompe disease, licensed to Shionogi with a $150 million upfront payment, and neurology and ophthalmology collaborations that validate the Compass platform and diversify potential future revenue.